These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38927944)

  • 1. Mixtures of Three Mortaparibs with Enhanced Anticancer, Anti-Migration, and Antistress Activities: Molecular Characterization in p53-Null Cancer Cells.
    Wadhwa R; Yang S; Meidinna HN; Sari AN; Bhargava P; Kaul SC
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.
    Meidinna HN; Shefrin S; Sari AN; Zhang H; Dhanjal JK; Kaul SC; Sundar D; Wadhwa R
    Front Cell Dev Biol; 2022; 10():918970. PubMed ID: 36172283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
    Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
    J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53
    Elwakeel A; Sari AN; Dhanjal JK; Meidinna HN; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Characterization of Mortaparib
    Sari AN; Elwakeel A; Dhanjal JK; Kumar V; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34647577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational and in vitro experimental analyses of the Anti-COVID-19 potential of Mortaparib and MortaparibPlus.
    Kumar V; Sari AN; Meidinna HN; Dhanjal JK; Subramani C; Basu B; Kaul SC; Vrati S; Sundar D; Wadhwa R
    Biosci Rep; 2021 Oct; ():. PubMed ID: 34605873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is Mortalin a Potential Therapeutic Target for Cancer?
    Yoon AR; Wadhwa R; Kaul SC; Yun CO
    Front Cell Dev Biol; 2022; 10():914540. PubMed ID: 35859897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
    Nigam N; Grover A; Goyal S; Katiyar SP; Bhargava P; Wang PC; Sundar D; Kaul SC; Wadhwa R
    PLoS One; 2015; 10(9):e0138192. PubMed ID: 26376435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and functional characterization of nuclear mortalin in human carcinogenesis.
    Ryu J; Kaul Z; Yoon AR; Liu Y; Yaguchi T; Na Y; Ahn HM; Gao R; Choi IK; Yun CO; Kaul SC; Wadhwa R
    J Biol Chem; 2014 Sep; 289(36):24832-44. PubMed ID: 25012652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.
    Pham MQ; Tran THV; Pham QL; Gairin JE
    Fundam Clin Pharmacol; 2019 Aug; 33(4):385-396. PubMed ID: 30628118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cucurbitacin-B inhibits cancer cell migration by targeting mortalin and HDM2: computational and
    Huifu H; Shefrin S; Yang S; Zhang Z; Kaul SC; Sundar D; Wadhwa R
    J Biomol Struct Dyn; 2024 Mar; 42(5):2643-2652. PubMed ID: 37129211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
    Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
    Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characterization and Enhancement of Anticancer Activity of Caffeic Acid Phenethyl Ester by γ Cyclodextrin.
    Wadhwa R; Nigam N; Bhargava P; Dhanjal JK; Goyal S; Grover A; Sundar D; Ishida Y; Terao K; Kaul SC
    J Cancer; 2016; 7(13):1755-1771. PubMed ID: 27698914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Caffeic Acid Phenethyl Ester-Mortalin Antibody Nanoparticles Offer Enhanced Selective Cytotoxicity to Cancer Cells.
    Wang J; Bhargava P; Yu Y; Sari AN; Zhang H; Ishii N; Yan K; Zhang Z; Ishida Y; Terao K; Kaul SC; Miyako E; Wadhwa R
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: Bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action.
    Sari AN; Bhargava P; Dhanjal JK; Putri JF; Radhakrishnan N; Shefrin S; Ishida Y; Terao K; Sundar D; Kaul SC; Wadhwa R
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy.
    Lu WJ; Lee NP; Kaul SC; Lan F; Poon RT; Wadhwa R; Luk JM
    Cell Death Differ; 2011 Jun; 18(6):1046-56. PubMed ID: 21233847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells.
    Wadhwa R; Takano S; Taira K; Kaul SC
    J Gene Med; 2004 Apr; 6(4):439-44. PubMed ID: 15079818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of mortalin to cancer cell stemness and cancer therapy.
    Yun CO; Bhargava P; Na Y; Lee JS; Ryu J; Kaul SC; Wadhwa R
    Sci Rep; 2017 Feb; 7():42016. PubMed ID: 28165047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics-based identification of novel natural mortalin-p53 abrogators as anticancer agents.
    Nagpal N; Goyal S; Dhanjal JK; Ye L; Kaul SC; Wadhwa R; Chaturvedi R; Grover A
    J Recept Signal Transduct Res; 2017 Feb; 37(1):8-16. PubMed ID: 27380217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.